JJJonas Laerte Longen Junior

Jonas Laerte Longen Junior

*This is an algorithmically generated author record based on publicly available information.

Jonas Laerte Longen Junior has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Therapeutic potential of flavonoid-rich plants in the treatment of arterial hypertension and diabetes mellitus: focus on antioxidant role

    by Matheus Vinicius Barbosa da Silva, Gleyciele dos Santos Barbosa, Alisson Carlos da Rocha, Diego da Rocha, Thais Ana da Silva, Jackson Alves da Silva, Alyssa Castelo Branco Alencar Andrade, Bruna Bezerra Pimentel Andrade, Francisco Antonio da Cruz dos Santos, Jonas Laerte Longen Junior, et al.

    Introduction: Chronic non-communicable diseases are the main causes of morbidity and mortality today, among them, Arterial Hypertension (SAH) and Type 2 Diabetes Mellitus (T2DM), which are responsible for a variety of systemic complications. Both conditions share, in their pathophysiology, the state of oxidative stress, justifying the possible use of antioxidant components, such as flavonoids. Objectives: To characterize and describe the therapeutic potential of the main medicinal plants of popular use, rich in flavonoid-type antioxidant constituents, in the treatment of hypertension and diabetes. Methodology: An integrative literature review study, developed from a survey in PubMed, MEDLINE and LILACS databases. Results: From the survey, the following plants used for hypertension stood out: Hibiscus sabdariffa, Allium sativum L., Phyllathus amarus, Ginkgo biloba and Matricaria chamomilla. As for diabetes, the following stand out: Syzygium cumini L., Caesalpinia sappan, Andrographis paniculata and Curcuma longa L. Conclusion: The results showed that the use of medicinal plants rich in flavonoids can serve as an important ally in the prevention, control and treatment. of SAH and T2DM, acting mainly against the state of oxidative stress, a common pathophysiological mechanism in both diseases, and thus preventing the occurrence of complications resulting from this state.


  • Open Access

    O agravamento das doenças reumáticas pós Covid 19: uma revisão integrativa

    by Ana Gabriella Costa Curado, Gustavo Moura Bruder, Beatriz Lima da Costa, Giovanna de Melo Gasques, Isabella Ramos Cruz, Daniel Machado Moura, Tatiana Yoshida Minakami, Igor Almeida Teixeira da Silva de Figueiredo, Jonas Laerte Longen Junior, Hallamark Alvarez Lemos Portella

    Introduction: COVID-19 is a disease caused by the new coronavirus, called SARS-CoV-2, an RNA virus, which initially emerged in Wuhan, China, in December 2019. asymptomatic and severe conditions, especially in patients with previous pathologies, such as patients with rheumatologic diseases. Method: The work was carried out in the form of an integrative review of the literature, it aimed to bring together the studies and identify the possible complications that rheumatic diseases would have in patients who contract COVID-19. Results/Discurssion: In view of the current health situation, the analysis of the studies showed that both COVID-19 and rheumatic diseases present a pathogenic cytokine, among the diseases rheumatoid arthritis, lupus erythematosus and primary Sjogren's spindrome. Conclusion: The work presented difficulties during its production, the greatest difficulty was the lack of literature that addresses the subject. Therefore, patients with DRIM must be evaluated individually and dimensioned for each clinical situation, especially in situations where COVID is suspected, in these cases the rheumatologist has a fundamental role in decision-making.